Results 31 to 40 of about 365,681 (229)

Relationship between serum prostate-specific antigen and age in cadavers

SAGE Open Medicine, 2020
Objectives: An increase in number of unidentified cadavers is a growing problem. To identify these cadavers, a simple objective method is required to estimate cadaveric age.
Hajime Tsuboi, Daisuke Miyamori, Noboru Ishikawa, Hiroaki Ichioka, Hiroshi Ikegaya   +4 more
doaj   +1 more source

Western Blotting Analysis of Antibodies to Prostate-Specific Antigen: Specificities for Prostate-Specific Antigen and Prostate-Specific Antigen Fragments

Tumor Biology, 1999
Approximately 40% of the prostate-specific antigen (PSA) purified from seminal fluid comprises cleaved or fragmented forms of PSA. These fragments are observed by reduced SDS-PAGE and have been identified in preparations of purified seminal plasma. The comparative analysis of 53 antibodies, submitted to an international PSA Workshop, with different PSA
T J, Wang, H J, Linton, R L, Sokoloff, L S, Grauer, H G, Rittenhouse, R L, Wolfert   +5 more
openaire   +2 more sources

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer

Baghdad Journal of Biochemistry and Applied Biological Sciences, 2020
Background: Prostate cancer is one of the most common cancers in men, worldwide. Many markers are suggested for prostate cancer with different specificity and sensitivity.
Amal A. Hussein, Rayah Baban, Alaa Hussein   +2 more
doaj  

PROSTATE-SPECIFIC ANTIGEN VELOCITY AND REPEATED MEASURES OF PROSTATE-SPECIFIC ANTIGEN

Urologic Clinics of North America, 1997
Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer.
H B, Carter, J D, Pearson
openaire   +2 more sources

Frequency of KLK3 gene deletions in the general population [PDF]

, 2016
Background One of the kallikrein genes ( KLK3) encodes prostate-specific antigen, a key biomarker for prostate cancer. A number of factors, both genetic and non-genetic, determine variation of serum prostate-specific antigen concentrations in the ...
Alghamdi, Osama, Alharbi, Khalid K, Day, Ian, Gaunt, Tom, Guthrie, Philip, McArdle, Wendy, Rodriguez, Santi, Shihab, Hashem   +7 more
core   +2 more sources

Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients [PDF]

, 2013
<br>Background:Prostate cancer cell growth is dependent upon androgen receptor (AR) activation, which is regulated by specific kinases. The aim of the current study is to establish if AR phosphorylation by Cdk1 or ERK1/2 is of prognostic ...
BV Kallakury, C E Adams, C Tannahill, D Gioeli, D Gioeli, G Fyffe, GG Kuiper, H Y Leung, H Zong, HY Wong, J Edwards, J Ferlay, J M Willder, JC Obenauer, JS Diallo, K Shigemura, KS McCarty, LA Ponguta, LJ Blok, M A Underwood, M Mistry, M Roach, M Seywright, MS Cookson, NG Anderson, P Chymkowitch, P G Horgan, P McCall, R Mukherjee, RE Bakin, RK Tyagi, S Chen, S Chen, S J Heng, SM Powell, T Kirkegaard, T Ohta, WC Bell, Y Wen, Z Fu, ZX Zhou   +40 more
core   +1 more source

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer

BMC Cancer, 2019
Background Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes in prostate-specific antigen while on abiraterone in patients with metastatic castrate-resistant prostate cancer potentially have financial and ...
Joshua P. Schiff, Patrick Cotogno, Allison Feibus, Peter Steinwald, Elisa Ledet, Brian Lewis, Oliver Sartor   +6 more
doaj   +1 more source

Clinical Implications of Nadir Serum Prostate-Specific Antigen Levels After Transurethral Enucleation of the Prostate

Frontiers in Oncology, 2022
ObjectiveProstate-specific antigen levels after transurethral enucleation of the prostate may serve as indicators of residual cancer foci. The objective of this study was to investigate the association between the post-transurethral enucleation of the ...
Yung-Ting Cheng, Yung-Ting Cheng, Jian-Hua Hong, Yu-Chuan Lu, Yi-Kai Chang, Shih-Chun Hung, Kuo-Kang Feng, Shih-Ping Liu, Po-Ming Chow, Hong-Chiang Chang, Chung-Hsin Chen, Yeong-Shiau Pu   +11 more
doaj   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source